Big Pharma's clinical trials in China are quietly bypassing global oversight, raising urgent alarms about data transparency and ethical practices. This emerging gap poses a serious risk to the trust and integrity of drug approvals worldwide
Big Pharma's clinical trials in China are quietly bypassing global oversight, raising urgent alarms about data transparency and ethical practices. This emerging gap poses a serious risk to the trust and integrity of drug approvals worldwide
